Braeburn

FDA Accepts Braeburn’s Drug Application Resubmission for BRIXADI for Moderate to Severe Opioid Use Disorder

PLYMOUTH MEETING, PA — Braeburn announced that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injection for subcutaneous (SC) use (CIII) for moderate to severe opioid …

FDA Accepts Braeburn’s Drug Application Resubmission for BRIXADI for Moderate to Severe Opioid Use Disorder Read More